title: Caffeine and a selective adenosine A(2B) receptor antagonist but not imidazoline receptor antagonists modulate antinociception induced by diphenyl diselenide in mice.
abstract: The present study examined the antinociceptive effect of diphenyl diselenide (PhSe)2, given orally (p.o.), in the hot-plate test in mice. The administration of diphenyl diselenide (10-100 mg/kg, p.o.) caused a significant inhibition of thermal nociception induced by hot-plate test in mice. Pretreatment of animals by intraperitoneal route (i.p.) with caffeine (10 mg/kg; a non-specific adenosine receptor antagonist) and PSB1115 (1 mg/kg; an adenosine A(2B) receptor antagonist), but not DPCPX (2 mg/kg; an adenosine A(1) receptor antagonist) and SCH5826 (3 mg/kg; an adenosine A(2A) receptor antagonist) significantly blockaded the antinociceptive effect caused by diphenyl diselenide (10 mg/kg, p.o.) in the hot-plate test. Moreover, the pretreatment of animals with efaroxan (1 mg/kg, i.p.; a mixed I(1) imidazoline/alpha(2)-adrenoceptor antagonist) and idazoxan (3 mg/kg, i.p.; a mixed I(2) imidazoline/alpha(2)-adrenoceptor antagonist) did not significantly reverse the antinociception caused by oral administration of diphenyl diselenide (10 mg/kg, p.o.) in the hot-plate test. These results indicate that diphenyl diselenide produced antinociception in a thermal model of pain in mice and its effect was prevented by caffeine and by a selective adenosine A(2B) receptor, but not by imidazoline receptor antagonists in mice.
authors: Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.
authors: Lucielli
authors: L
authors: Savegnago
authors: Cristiano R
authors: CR
authors: Jesse
authors: Cristina W
authors: CW
authors: Nogueira
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal; D001555:Benzene Derivatives / Q000627:therapeutic use*; D001572:Benzofurans / Q000494:pharmacology; D002110:Caffeine / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000494:pharmacology; D007274:Injections, Intraperitoneal / Q000379:methods; D008297:Male; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology; D016566:Organoselenium Compounds / Q000627:therapeutic use*; D010147:Pain Measurement; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
chemical_list: C518874:1-propyl-8-(4-sulfophenyl)xanthine; C098657:5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; D000317:Adrenergic alpha-Antagonists; D001555:Benzene Derivatives; D001572:Benzofurans; D007093:Imidazoles; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; D010726:Phosphodiesterase Inhibitors; D011743:Pyrimidines; D014230:Triazoles; D014970:Xanthines; C061132:diphenyldiselenide; D002110:Caffeine; C051360:1,3-dipropyl-8-cyclopentylxanthine; C062597:efaroxan